Brief India: SAIL: Leaner, Stronger, Poised for Recovery — Margins to Rebound in H2 and more
In this briefing: SAIL: Leaner, Stronger, Poised for Recovery — Margins to Rebound in H2 APAC Healthcare Weekly (November 2) – Takeda, Eisai, Wuxi AppTec, Celltrion, CSL, PharmaEssentia India Finally Showing Signs of Life; Remain Overweight Taiwan, China, Korea, and the U.S. HSIE Results Daily: Larsen & Toubro, Jindal Steel, Shree Cement, PB Fintech MCX: Index Options: Paving the Next Phase of Growth. Maintain BUY 1. SAIL: Leaner, Stronger, Poised for Recovery — Margins to Rebound in H2 Steady operations despite price softness; volumes up 8% YoY, debt down ₹3,400 Cr, margins stable around 10%. Capex on track; IISCO ₹33,000 Cr expansion progressing, funded via internal accruals and moderate leverage. Valuation reasonable; trades at ~7× EV/EBITDA and ~US$560/t EV/Ton with Positive Bias on margin recovery and balance-sheet strength. 2. APAC Healthcare Weekly (November 2) – Takeda, Eisai, Wuxi AppTec, Celltrion, CSL, PharmaEssentia Takeda has dropped AstraZeneca-partnered antibody drug candidate from its pipeline.